Eficacia, toxicidad y tolerabilidad de los esquemas antirretrovirales en pacientes con infección por virus de inmunodeficiencia humana. Hospital Vicente Corral Moscoso. Cuenca. 2009 – 2016.

Abstract

OBJECTIVE: To determine the efficacy, toxicity and tolerability of antiretroviral regimens used in patients with HIV in outpatient clinics. MATERIALS AND METHODS: Observational cohort study, prospective - retrospective. The universe corresponded to patients who attended the consultation (2009 - 2016). The data was collected after authorizations and respective informed consent signatures. Viral load and CD4 T lymphocytes were performed to verify efficacy. When studying the indirect toxicity, hematic biometrics, liver, kidney and lipid profile were performed. The tolerability was established by the presence of diarrhea, nausea, vomiting or abdominal pain. The information was analyzed in the SPSS software; for the hypothesis test, relative risk, 95% confidence interval and p <0.05 value were used. RESULTS: 300 patients were studied in two cohorts: the first included the scheme administered in one dose per day: Tenofovir / Emtricitabine / Efavirenz (162 patients - 54%) and in the second, schemes were included that were administered in two or more doses (138 patients - 46%). In both cohorts an efficacy of 90.7% and 95.7% respectively was found; non-significant difference (RR: 0.94, CI: 95% 0.89 - 1.008 and p-value: 0.07). Indirect toxicity was determined in 17.9% and 23% respectively; non-significant difference (RR: 1.74, CI: 95% 0.48 - 1.16 and p-value: 0.12). The tolerability was established in 80.2% and 50.7% respectively; significant difference (RR: 1.58, CI: 95% 1.31 - 1.89 and p-value: 0.00). CONCLUSIONS: Regarding efficacy and indirect toxicity, both cohorts were similar (optimal levels). The single dose was better tolerated.